The core team at YENO, led by Claudia Bettina Klein and Hubertus Baumgartner, combines interdisciplinary knowledge and visionary implementation skills: technical and biophysical expertise meets strategic competence and entrepreneurial skill.

 

The joint ownership of the EU and US patent for the “GENOS method” underscores the company's ambition to play a key role in shaping integrative medicine, from cellular regulation to its application in practice and therapy. With the GENOS method, the various GENOS infusions, GENOS oral medication, and GENOS Fibrocell Rejuvenation Infusion.